Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
<div><p>Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and mod...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , |
| Published: |
2023
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513526554427392 |
|---|---|
| author | Gunjan Dagar (9339276) |
| author2 | Ashna Gupta (14150955) Tariq Masoodi (8117702) Sabah Nisar (12561961) Maysaloun Merhi (4246147) Sheema Hashem (14150961) Ravi Chauhan (14150958) Manisha Dagar (9339273) Sameer Mirza (685921) Puneet Bagga (4055866) Rakesh Kumar (8432) Ammira S. Al-Shabeeb Akil (15376391) Muzafar A. Macha (11605200) Mohammad Haris (564809) Shahab Uddin (154400) Mayank Singh (793077) Ajaz A. Bhat (12984701) |
| author2_role | author author author author author author author author author author author author author author author author |
| author_facet | Gunjan Dagar (9339276) Ashna Gupta (14150955) Tariq Masoodi (8117702) Sabah Nisar (12561961) Maysaloun Merhi (4246147) Sheema Hashem (14150961) Ravi Chauhan (14150958) Manisha Dagar (9339273) Sameer Mirza (685921) Puneet Bagga (4055866) Rakesh Kumar (8432) Ammira S. Al-Shabeeb Akil (15376391) Muzafar A. Macha (11605200) Mohammad Haris (564809) Shahab Uddin (154400) Mayank Singh (793077) Ajaz A. Bhat (12984701) |
| author_role | author |
| dc.creator.none.fl_str_mv | Gunjan Dagar (9339276) Ashna Gupta (14150955) Tariq Masoodi (8117702) Sabah Nisar (12561961) Maysaloun Merhi (4246147) Sheema Hashem (14150961) Ravi Chauhan (14150958) Manisha Dagar (9339273) Sameer Mirza (685921) Puneet Bagga (4055866) Rakesh Kumar (8432) Ammira S. Al-Shabeeb Akil (15376391) Muzafar A. Macha (11605200) Mohammad Haris (564809) Shahab Uddin (154400) Mayank Singh (793077) Ajaz A. Bhat (12984701) |
| dc.date.none.fl_str_mv | 2023-07-07T03:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12967-023-04292-3 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Harnessing_the_potential_of_CAR-T_cell_therapy_progress_challenges_and_future_directions_in_hematological_and_solid_tumor_treatments/25257169 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biological sciences Biochemistry and cell biology Genetics CAR-T cell therapy Immunotherapy Tumor antigens Antigen escape Cytokine release syndrome Hematological malignancy Solid tumor |
| dc.title.none.fl_str_mv | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Journal of Translational Medicine<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-023-04292-3" target="_blank">https://dx.doi.org/10.1186/s12967-023-04292-3</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_6b528b99b01ebc389b767b624c62a3ab |
| identifier_str_mv | 10.1186/s12967-023-04292-3 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25257169 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatmentsGunjan Dagar (9339276)Ashna Gupta (14150955)Tariq Masoodi (8117702)Sabah Nisar (12561961)Maysaloun Merhi (4246147)Sheema Hashem (14150961)Ravi Chauhan (14150958)Manisha Dagar (9339273)Sameer Mirza (685921)Puneet Bagga (4055866)Rakesh Kumar (8432)Ammira S. Al-Shabeeb Akil (15376391)Muzafar A. Macha (11605200)Mohammad Haris (564809)Shahab Uddin (154400)Mayank Singh (793077)Ajaz A. Bhat (12984701)Biological sciencesBiochemistry and cell biologyGeneticsCAR-T cell therapyImmunotherapyTumor antigensAntigen escapeCytokine release syndromeHematological malignancySolid tumor<div><p>Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Journal of Translational Medicine<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s12967-023-04292-3" target="_blank">https://dx.doi.org/10.1186/s12967-023-04292-3</a></p>2023-07-07T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12967-023-04292-3https://figshare.com/articles/journal_contribution/Harnessing_the_potential_of_CAR-T_cell_therapy_progress_challenges_and_future_directions_in_hematological_and_solid_tumor_treatments/25257169CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/252571692023-07-07T03:00:00Z |
| spellingShingle | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments Gunjan Dagar (9339276) Biological sciences Biochemistry and cell biology Genetics CAR-T cell therapy Immunotherapy Tumor antigens Antigen escape Cytokine release syndrome Hematological malignancy Solid tumor |
| status_str | publishedVersion |
| title | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| title_full | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| title_fullStr | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| title_full_unstemmed | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| title_short | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| title_sort | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments |
| topic | Biological sciences Biochemistry and cell biology Genetics CAR-T cell therapy Immunotherapy Tumor antigens Antigen escape Cytokine release syndrome Hematological malignancy Solid tumor |